Advanced search
Publication Cover
Renal Failure Volume 38, 2016 - Issue 9
Submit an article Journal homepage
767
Views
9
CrossRef citations to date
0
Altmetric
Clinical Study

High mobility group box 1 and tumor growth factor β: useful biomarkers in pediatric patients receiving peritoneal dialysis

Roberto ChimenzDepartment of Pediatric Sciences, Unit of Pediatric Nephrology and Rheumatology, University of Messina, Messina, Italy;
,
Antonio LacquanitiDepartment of Clinical and Experimental Medicine, Division of Nephrology and Dialysis, University of Messina, Messina, ItalyCorrespondence[email protected]
,
Laura ColavitaDepartment of Pediatric Sciences, Unit of Pediatric Nephrology and Rheumatology, University of Messina, Messina, Italy;
,
Valeria ChiricoDepartment of Pediatric Sciences, Unit of Pediatric Nephrology and Rheumatology, University of Messina, Messina, Italy;
,
Claudia FedeDepartment of Pediatric Sciences, Unit of Pediatric Nephrology and Rheumatology, University of Messina, Messina, Italy;
,
Michele BuemiDepartment of Clinical and Experimental Medicine, Division of Nephrology and Dialysis, University of Messina, Messina, Italy
&
Carmelo FedeDepartment of Pediatric Sciences, Unit of Pediatric Nephrology and Rheumatology, University of Messina, Messina, Italy;
show all
Pages 1370-1376 | Received 19 Feb 2016, Accepted 20 Jul 2016, Published online: 08 Aug 2016

References

  • Schaefer F, Borzych-Duzalka D, Azocar M, et al. Impact of global economic disparities on practices and outcomes of chronic peritoneal dialysis in children: Insights from the International Pediatric Peritoneal Dialysis Network Registry. Perit Dial Int. 2012;32:399–409.
  • Li PK, Szeto CC, Piraino B, et al. Peritoneal dialysis-related infections recommendations: 2010 update. Perit Dial Int. 2010;30:393–423.
  • Chaudhary K, Khanna R. Biocompatible peritoneal dialysis solutions: Do we have one? Clin J Am Soc Nephrol. 2010;5:723–732.
  • Amore A, Cappelli G, Cirina P, et al. Glucose degradation products increase apoptosis of human mesothelial cells. Nephrol Dial Transplant. 2003;18:677–688.
  • Conti G, Amore A, Cirina P, et al. Glycated adducts induce mesothelial cell transdifferentiation: Role of glucose and icodextrin dialysis solutions. J Nephrol. 2008;21:426–437.
  • Lacquaniti A, Chirico V, Mondello S, et al. Neutrophil gelatinase-associated lipocalin in peritoneal dialysis reflects status of peritoneum. J Nephrol. 2013;26:1151–1159.
  • Williams JD, Craig KJ, Topley N, et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol. 2002;13:470–479.
  • Chirico V, Lacquaniti A, Salpietro V, et al. High-mobility group box 1 (HMGB1) in childhood: From bench to bedside. Eur J Pediatr. 2014;173:1123–1136.
  • Arrigo T, Chirico V, Salpietro V, et al. High-mobility group protein B1: A new biomarker of metabolic syndrome in obese children. Eur J Endocrinol. 2013;168:631–638.
  • Opatrna S, Popperlova A, Kalousová M, Zima T. Low glucose degradation product peritoneal dialysis regimen is associated with lower plasma EN-RAGE and HMGB-1 proinflammatory ligands of receptor for advanced glycation end products. Ther Apher Dial. 2014;18:309–316.
  • Cernaro V, Lacquaniti A, Lupica R, et al. Relaxin: New pathophysiological aspects and pharmacological perspectives for an old protein. Med Res Rev. 2014;34:77–105.
  • Cernaro V, Lacquaniti A, Donato V, Fazio MR, Buemi A, Buemi M. Fibrosis, regeneration and cancer: What is the link? Nephrol Dial Transplant. 2012;27:21–27.
  • Warady BA, Bakkaloglu S, Newland J, et al. Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update. Perit Dial Int. 2012;32:32–86.
  • Twardowski ZJ, Nolph KO, Khanna R, et al. Peritoneal equilibration test. Perit Dial Bull. 1987;7:138–147.
  • van Biesen W, Heimburger O, Krediet R, et al. Evaluation of peritoneal membrane characteristics: Clinical advice for prescription management by the ERBP working group. Nephrol Dial Transplant. 2010;25:2052–2062.
  • Chirico V, Lacquaniti A, Leonardi S, et al. Acute pulmonary exacerbation and lung function decline in patients with cystic fibrosis: High-mobility group box 1 (HMGB1) between inflammation and infection. Clin Microbiol Infect. 2014;21:368.e1–369.
  • Chirico V, Lacquaniti A, Piraino B, et al. Thalassaemia major and infectious risk: High mobility group box-1 represents a novel diagnostic and prognostic biomarker. Br J Haematol. 2015;171:130–136.
  • Cao S, Li S, Li H, et al. The potential role of HMGB1 release in peritoneal dialysis-related peritonitis. PLoS One. 2013;8:e54647.
  • Zhu N, Yuan W, Zhou Y, et al. High mobility group box protein-1 correlates with microinflammatory state and nutritional status in continuous ambulatory peritoneal dialysis patients. J Artif Organs. 2011;14:125–132.
  • Lacquaniti A, Bolignano D, Campo S, et al. Malnutrition in the elderly patient on dialysis. Ren Fail. 2009;31:239–245.
  • Vidal E, Edefonti A, Puteo F, et al. Encapsulating peritoneal sclerosis in paediatric peritoneal dialysis patients: The experience of the Italian Registry of Pediatric Chronic Dialysis. Nephrol Dial Transplant. 2013;28:1603–1609.
  • Stompór T, Zdzienicka A, Motyka M, Dembińska-Kieć A, Davies SJ, Sulowicz W. Selected growth factors in peritoneal dialysis: Their relationship to markers of inflammation, dialysis adequacy, residual renal function, and peritoneal membrane transport. Perit Dial Int. 2002;22:670–676.
  • Zweers MM, de Waart DR, Smit W, Struijk DG, Krediet RT. Growth factors VEGF and TGF-beta1 in peritoneal dialysis. J Lab Clin Med. 1999;134:124–132.
  • Wong TY, Szeto CC, Lai KB, Lam CW, Lai KN, Li PK. Longitudinal study of peritoneal membrane function in continuous ambulatory peritoneal dialysis: Relationship with peritonitis and fibrosing factors. Perit Dial Int. 2000;20:679–685.
  • Yavaşcan Ö, Aksu N, Alparslan C, et al. The importance of ultrasonographic measurement of peritoneal wall thickness in pediatric chronic peritoneal dialysis patients. Ren Fail. 2015;37:381–386.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.